Skip to main content
MEHA
NASDAQ Life Sciences

CFO Urges Shareholders to Vote on Reverse Split to Avoid Delisting

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$0.077
Mkt Cap
$3.27M
52W Low
$0.057
52W High
$8
Market data snapshot near publication time

summarizeSummary

Functional Brands' CFO issued an urgent letter to shareholders, emphasizing the critical need for proxy votes by May 28, 2026, to approve a reverse stock split and avoid Nasdaq delisting.


check_boxKey Events

  • Urgent Vote Solicitation

    Functional Brands' CFO, David Wells, issued a direct letter to certain stockholders, urgently requesting their proxy votes for the Special Meeting on May 28, 2026.

  • Critical Reverse Stock Split Vote

    The solicitation aims to secure shareholder approval for a reverse stock split, a measure previously disclosed as essential to meet Nasdaq listing requirements and avoid delisting.

  • Risk of Meeting Delay

    The CFO explicitly stated the company needs shareholder support to avoid delaying or adjourning the special meeting, indicating challenges in reaching the required vote threshold.

  • Context of Major Acquisition

    This urgent vote follows the company's announcement of a binding Letter of Intent to acquire BullionFX | Alchemy assets for $142.9 million, an acquisition that is highly dilutive and likely contingent on the company's continued listing.


auto_awesomeAnalysis

This filing highlights Functional Brands' urgent need to secure shareholder approval for a reverse stock split, which is critical for maintaining its Nasdaq listing and enabling the recently announced $142.9 million acquisition of BullionFX | Alchemy assets. The direct, personalized appeal from the CFO indicates the company is struggling to gather sufficient votes, underscoring the precariousness of its situation given prior going concern warnings and recent financial losses. Failure to pass this vote could lead to delisting and jeopardize the acquisition.

At the time of this filing, MEHA was trading at $0.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.06 to $8.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed MEHA - Latest Insights

MEHA
May 21, 2026, 5:15 PM EDT
Filing Type: DEFA14A
Importance Score:
9
MEHA
May 20, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
MEHA
May 19, 2026, 5:00 PM EDT
Filing Type: DEFA14A
Importance Score:
9
MEHA
May 15, 2026, 5:11 PM EDT
Source: Wiseek News
Importance Score:
9
MEHA
May 15, 2026, 5:03 PM EDT
Filing Type: 10-Q
Importance Score:
10
MEHA
May 11, 2026, 5:45 PM EDT
Filing Type: 8-K
Importance Score:
8
MEHA
May 11, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
10
MEHA
May 11, 2026, 8:00 AM EDT
Source: TMX Newsfile
Importance Score:
10
MEHA
Apr 27, 2026, 4:15 PM EDT
Filing Type: DEF 14A
Importance Score:
8
MEHA
Apr 22, 2026, 8:00 AM EDT
Source: TMX Newsfile
Importance Score:
7